(Q37919896)

25 August 2017

1 reference

title

The future of cell culture-based influenza vaccine production (English)

1 reference

25 August 2017

1 reference

0 references

Michael L Perdue

1

1 reference

25 August 2017

Frank Arnold

2

1 reference

25 August 2017

Sheng Li

3

1 reference

25 August 2017

Armen Donabedian

4

1 reference

25 August 2017

Vittoria Cioce

5

1 reference

25 August 2017

Thomas Warf

6

1 reference

25 August 2017

Robert Huebner

7

1 reference

25 August 2017

1 August 2011

1 reference

Expert Review of Vaccines

25 August 2017

1 reference

25 August 2017

10

1 reference

25 August 2017

8

1 reference

25 August 2017

1183-1194

1 reference

Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.

25 August 2017

1 reference

Development and strategies of cell-culture technology for influenza vaccine

21 January 2018

1 reference

Continuous cell lines as a production system for influenza vaccines.

21 January 2018

1 reference

Vaccines against seasonal and pandemic influenza and the implications of changes in substrates for virus production.

21 January 2018

1 reference

Suspension-Vero cell cultures as a platform for viral vaccine production

21 January 2018

1 reference

Replicative advantage in tissue culture of egg-adapted influenza virus over tissue-culture derived virus: implications for vaccine manufacture

21 January 2018

1 reference

A brief history of polio vaccines

21 January 2018

1 reference

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin

21 January 2018

1 reference

FluBlok, a next generation influenza vaccine manufactured in insect cells

21 January 2018

1 reference

Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle

21 January 2018

1 reference

Influenza virus-like particle vaccines

21 January 2018

1 reference

Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses

21 January 2018

1 reference

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.

21 January 2018

1 reference

Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.

21 January 2018

1 reference

Using plant cells as influenza vaccine substrates.

21 January 2018

1 reference

Use of MDCK cells for production of live attenuated influenza vaccine

21 January 2018

1 reference

Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines.

21 January 2018

1 reference

Development of a mammalian cell (Vero) derived candidate influenza virus vaccine

21 January 2018

1 reference

The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines.

21 January 2018

1 reference

Scaling-up vaccine production: implementation aspects of a biomass growth observer and controller.

21 January 2018

1 reference

Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains

21 January 2018

1 reference

Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults.

21 January 2018

1 reference

Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial.

21 January 2018

1 reference

Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children

21 January 2018

1 reference

Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.

21 January 2018

1 reference

A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine

21 January 2018

1 reference

A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine

21 January 2018

1 reference

HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines.

21 January 2018

1 reference

Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK.

21 January 2018

1 reference

Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza

21 January 2018

1 reference

Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate.

21 January 2018

1 reference

The growth of attenuated influenza vaccine donor strains in continuous cell lines.

21 January 2018

1 reference

Live cold-adapted influenza A vaccine produced in Vero cell line

21 January 2018

1 reference

Development of cell culture (MDCK) live cold-adapted (CA) attenuated influenza vaccine

21 January 2018

1 reference

Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control.

21 January 2018

1 reference

United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world

21 January 2018

1 reference

Conversion of MDCK cell line to suspension culture by transfecting with human siat7e gene and its application for influenza virus production

21 January 2018

1 reference

Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media.

21 January 2018

1 reference

Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive c

21 January 2018

1 reference

Growth determinants for H5N1 influenza vaccine seed viruses in MDCK cells

21 January 2018

1 reference

Glycan analysis in cell culture-based influenza vaccine production: influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin.

21 January 2018

1 reference

High titer growth of human and avian influenza viruses in an immortalized chick embryo cell line without the need for exogenous proteases

21 January 2018

1 reference

Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.

21 January 2018

1 reference

Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).

21 January 2018

1 reference

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

21 January 2018

1 reference

A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.

21 January 2018

1 reference

Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines.

21 January 2018

1 reference

Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.

21 January 2018

1 reference

Cloning and assessment of tumorigenicity and oncogenicity of a Madin-Darby canine kidney (MDCK) cell line for influenza vaccine production

21 January 2018

1 reference

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.

21 January 2018

1 reference

Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults

21 January 2018

1 reference

Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets

21 January 2018

1 reference

Influenza is a major contributor to childhood pneumonia in a tropical developing country

21 January 2018

1 reference

Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.11.82

1 reference

25 August 2017

1 reference